Latest News
Get real-time updates on the latest news and developments in the pharmaceutical world. Stay informed about new drug launches, research findings, regulatory changes, and industry updates. Explore a wide range of topics and stay connected with the rapidly evolving world of pharma.
Elastin Biosciences Finds a Way to Restore Elastin and Treat Diseases
Longaevus Technologies is making waves with its recent spin-off from Elastin Biosciences, driven by groundbreaking preclinical results across three key ...
FDA grants breakthrough status to T-DXd for two HER2-positive cancers
Daiichi Sankyo and AstraZeneca have garnered FDA Breakthrough Therapy Designations (BTDs) for their Enhertu (T-DXd) therapy to treat two distinct ...
Otsuka acquires Mindset Pharma, a leader in psychedelic medicines for mental health
Japanese pharmaceutical giant Otsuka is embarking on a groundbreaking acquisition, setting its sights on Canada’s Mindset Pharma, a specialist in ...
Roche’s Alecensa beats chemo in early-stage lung cancer, following Tecentriq’s lead
With Tecentriq approval, Roche is once again celebrating success, this time in a promising early-stage lung cancer trial starring Alecensa, ...
GSK boosts vaccine production with €250M facility for shingles, RSV and malaria shots
As GlaxoSmithKline (GSK) continues to expand its vaccine portfolio with the introduction of the new respiratory syncytial virus (RSV) vaccine, ...
Amgen seals the deal with Horizon for $28 billion, expanding its portfolio of rare disease drugs
After several months of legal battles, Amgen has finally received the green light for its $27.8 billion acquisition of Horizon ...
Republican Governors Urge Congress to Act on U.S. Drug Shortages
Amid growing concerns over drug shortages in the US, a coalition of 11 Republican governors has penned a joint letter ...
Teva Wins License to Launch Generic Vivitrol in 2027 After Patent Settlement with Alkermes
Teva Pharmaceuticals has secured a pivotal victory in a patent dispute settlement with Alkermes, the manufacturer of Vivitrol. This settlement ...
J&J cuts TB drug price by 55% after giving up patent rights
Just seven weeks after announcing its willingness to permit generic competition for the drug-resistant tuberculosis (TB) treatment Sirturo (bedaquiline) in ...
Sanofi’s specialty care chief Sibold leaves amid executive reshuffle
After an impressive six-year tenure steering Sanofi’s specialty care division, Bill Sibold is bidding adieu to embrace a new external ...
Emergent Launches OTC Narcan to Fight Opioid Overdose Crisis
Emergent BioSolutions has initiated the rollout of an over-the-counter (OTC) iteration of its opioid overdose treatment, Narcan, amplifying its focus ...
Mesoblast CEO Slashes Salary by 30% to Fund Cell Therapy Trial
In a bold move reflecting commitment to the company’s mission, Mesoblast’s CEO has chosen to lead by example by implementing ...
Sage slashes 40% of staff, reshuffles leadership after zuranolone setback
Sage Therapeutics is set to undergo a significant transformation by reducing its workforce by 40% following a setback in gaining ...
Takeda’s Vyvanse faces generic competition after 16 years of ADHD dominance
Vyvanse, a blockbuster drug for attention-deficit/hyperactivity disorder (ADHD) and binge-eating disorder, has been the top choice for many patients and ...
Mezigdomide, a new oral drug for multiple myeloma, shows ‘modest’ survival benefit in phase 1 trial
A new oral drug for multiple myeloma, mezigdomide, has shown a ‘modest’ survival benefit in a phase 1 trial involving ...
Outlook’s eye drug Lytenava fails to win FDA approval, despite positive trial
Outlook Therapeutics has been working on a reformulated version of Roche’s cancer drug Avastin for the treatment of certain eye ...
AstraZeneca’s Farxiga confident of its edge over Novo’s Wegovy in heart failure market
Novo Nordisk’s semaglutide and AstraZeneca’s Farxiga assuming the roles of formidable contenders. The arena is no longer confined to blood ...
Serina Therapeutics merges with struggling AgeX Therapeutics to go public and advance its Parkinson’s drug
AgeX Therapeutics, a biotech that has been facing financial difficulties and stalled preclinical programs for years, has finally found a ...
Another Phase 3 flop for FibroGen as DMD drug fails to improve mobility
FibroGen’s troubles continue to mount. The biotech announced its fourth phase 3 failure in four months after the market closed ...
Pfizer and BioNTech challenge Moderna’s mRNA vaccine patents in a bid to end monopoly
The legal battle between Moderna and its rivals Pfizer and BioNTech over the patents related to mRNA vaccine production is ...
Cencora: The new name of the pharma giant formerly known as AmerisourceBergen
After more than two decades of being known as AmerisourceBergen, the pharmaceutical services company has decided to rebrand itself as ...
Novo Nordisk acquires Embark Biotech for 15 million euros in obesity deal spree
Novo Nordisk has made another move to expand its obesity portfolio, acquiring Embark Biotech for 15 million euros ($16 million) ...
Tecentriq SC: A Swift Leap Forward in Cancer Treatment Receives Green Light
Roche has proudly unveiled that Tecentriq SC (atezolizumab) has received the stamp of approval from the Medicines and Healthcare products ...
Roche’s Evrysdi Illuminates Hope: EC Expands Approval for SMA Infants
To provide a brighter future for infants battling spinal muscular atrophy (SMA), Roche has unveiled a momentous development. The European ...
3M Reaches Historic Settlement: The Sound of Justice Rings Louder
3M, the manufacturing giant, has concluded a chapter that involved battling allegations of knowingly distributing defective earplugs to the US ...
Sandoz Acquires Mycamine, a Top Antifungal Drug, from Astellas
In the ever-evolving landscape of medical advancements, Sandoz emerges as a dominant force, orchestrating a strategic move that echoes across ...
Activist Investors Renew Battle Against Biotech Pioneering Long COVID Treatment at AIM Immunotech
In the ever-shifting landscape of corporate battles, AIM Immunotech finds itself once again on the front lines, grappling with a ...
Bracing for Change: CMS Unveils Drug Price Negotiation Targets Amid Industry Backlash
The day that pharmaceutical manufacturers have been cautiously eyeing has finally dawned – Tuesday saw the grand revelation of the ...
Bristol Myers Squibb’s Bold Robotic Alliance with Cellares for Advanced CAR-T Production
In the realm of cutting-edge cell therapy, where innovation is the heartbeat and the promise of transformative treatments is the ...
Navigating the Maze of “Bad Cholesterol”: A Wake-Up Call for Heart Survivors
In the delicate realm of heart health, where knowledge often stands as a shield against future battles, a surprising chasm ...
